6625-94-1

Basic information

• Product Name: 2,4,7-TRICHLOROQUINAZOLINE
• Synonyms: 2,4,7-TRICHLOROQUINAZOLINE;2,4-Dichloro-7-chloroquinazoline
• CAS NO: 6625-94-1
• Molecular Formula: C₈H₃Cl₃N₂
• Molecular Weight: 233.48
• Mol File: 6625-94-1.mol
• Article Data: 19

Chemical Properties

• Melting Point: 127 °C
• Boiling Point: 309.1 °C at 760 mmHg
• Flash Point: 169.6 °C
• Appearance: /
• Density: 1.6 g/cm³
• Vapor Pressure: 0.00119mmHg at 25°C
• Refractive Index: 1.677
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -1.14±0.30(Predicted)
• CAS DataBase Reference: 2,4,7-TRICHLOROQUINAZOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4,7-TRICHLOROQUINAZOLINE(6625-94-1)
• EPA Substance Registry System: 2,4,7-TRICHLOROQUINAZOLINE(6625-94-1)

Safety Data

• Hazardous Substances Data: 6625-94-1(Hazardous Substances Data)

Usage

General Description

2,4,7-Trichloroquinazoline is a chemical compound with the molecular formula C9H4Cl3N3. It is a trichlorinated quinazoline derivative, which is a class of compounds commonly used in organic synthesis and pharmaceutical research. 2,4,7-Trichloroquinazoline has been studied for its potential applications in the development of new drugs and agrochemicals. It is known for its strong electron-withdrawing properties and has been used as a building block in the synthesis of various biologically active compounds. Additionally, it has been investigated for its potential as a corrosion inhibitor and in the production of polymers and dyes. Despite its potential applications, 2,4,7-Trichloroquinazoline and its derivatives may pose environmental and health risks and therefore require proper handling and disposal.

InChI:InChI=1/C8H3Cl3N2/c9-4-1-2-5-6(3-4)12-8(11)13-7(5)10/h1-3H

Upstream product

• 13165-35-0 7-chloroquinazoline-2,4-dione 
• 89-77-0 2-Amino-4-chlorobenzoic acid 
• 214288-97-8 4-chloro-2-ureido-benzoic acid 
• 6280-88-2 4-chloro-2-nitro-benzoic acid 

Downstream Products

• 111218-91-8 2,7-dichloro-quinazolin-4-ylamine 
• 20197-96-0 2,7-dichloro-3,4-dihydro-4-oxoquinazoline 
• 769158-10-3 2-((2,7-dichloro-4-oxoquinazolin-3(4H)-yl)methyl)benzonitrile 
• 187942-11-6 5,8-dichloro-3-(4-chlorophenyl)[1,2,4]triazolo[4,3-c]quinazoline 
• 186501-12-2 3-(4-Benzhydryl-piperazin-1-ylmethyl)-8-chloro-6H-imidazo[1,2-c]quinazolin-5-one 
• 111218-71-4 [4-(4-Amino-7-chloro-quinazolin-2-yl)-piperazin-1-yl]-furan-2-yl-methanone 
• 76004-91-6 7-Chloro-N²-(3,5-dichloro-phenyl)-N⁴-(1-ethyl-piperidin-3-yl)-quinazoline-2,4-diamine; hydrochloride 
• 76004-89-2 7-Chloro-N²-(3,4-dichloro-phenyl)-N⁴-(1-ethyl-piperidin-3-yl)-quinazoline-2,4-diamine; hydrochloride 
• 20197-96-0 2,7-dichloro-4-oxoquinazoline 

Relevant articles and documents

Synthesis and biological evaluation of 2-benzylaminoquinazolin-4(3H)-one derivatives as a potential treatment for SARS-CoV-2

Despite the continuing global crisis caused by coronavirus disease 2019 (COVID-19), there is still no effective treatment. Therefore, we designed and synthesized a novel series of 2-benzylaminoquinazolin-4(3H)-one derivatives and demonstrated that they ar

Design, synthesis and biological evaluation of 2-aminoquinazolin-4(3H)-one derivatives as potential SARS-CoV-2 and MERS-CoV treatments

Despite the rising threat of fatal coronaviruses, there are no general proven effective antivirals to treat them. 2-Aminoquinazolin-4(3H)-one derivatives were newly designed, synthesized, and investigated to show the inhibitory effects on SARS-CoV-2 and MERS-CoV. Among the synthesized derivatives, 7-chloro-2-((3,5-dichlorophenyl)amino)quinazolin-4(3H)-one (9g) and 2-((3,5-dichlorophenyl)amino)-5-hydroxyquinazolin-4 (3H)-one (11e) showed the most potent anti-SARS-CoV-2 activities (IC50 50 50 > 25 μM). In addition, both compounds showed acceptable results in metabolic stabilities, hERG binding affinities, CYP inhibitions, and preliminary PK studies.

Molecular Hybridization-Inspired Optimization of Diarylbenzopyrimidines as HIV-1 Nonnucleoside Reverse Transcriptase Inhibitors with Improved Activity against K103N and E138K Mutants and Pharmacokinetic Profiles

Molecular hybridization is a powerful strategy in drug discovery. A series of novel diarylbenzopyrimidine (DABP) analogues were developed by the hybridization of FDA-approved drugs etravirine (ETR) and efavirenz (EFV) as potential HIV-1 nonnucleoside reverse transcriptase inhibitors (NNRTIs). Substituent modifications resulted in the identification of new DABPs with the combination of the strengths of the two drugs, especially compound 12d, which showed promising activity toward the EFV-resistant K103N mutant. 12d also had a favorable pharmacokinetic (PK) profile with liver microsome clearances of 14.4 μL/min/mg (human) and 33.2 μL/min/mg (rat) and an oral bioavailability of 15.5% in rat. However, its activity against the E138K mutant was still unsatisfactory; E138K is the most prevalent NNRTI resistance-associated mutant in ETR treatment. Further optimizations resulted in a highly potent compound (12z) with no substituents on the phenyl ring and a 2-methyl-6-nitro substitution pattern on the 4-cyanovinyl-2,6-disubstitued phenyl motif. The antiviral activity of this compound was much higher than those of ETR and EFV against the WT, E138K, and K103N variants (EC50 = 3.4, 4.3, and 3.6 nM, respectively), and the cytotoxicity was decreased while the selectivity index (SI) was increased. In particular, this compound exhibited acceptable intrinsic liver microsome stability (human, 34.5 μL/min/mg; rat, 33.2 μL/min/mg) and maintained the good PK profile of its parent compound EFV and showed an oral bioavailability of 16.5% in rat. Molecular docking and structure-activity relationship (SAR) analysis provided further insights into the binding of the DABPs with HIV-1 reverse transcriptase and provided a deeper understanding of the key structural features responsible for their interactions.